VTR vs ZYME · P/E 149, rev $4.92B vs rev $76.3M
Ventas Inc (VTR) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
VTR currently screens at market cap $39.94B and trailing P/E 149.4. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the VTR and ZYME stock pages for the full models.
Not investment advice.